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Abstract: Background: Biomarkers that are indicative of early biochemical aberrations are needed
to predict the risk of dementia onset and progression in Alzheimer’s disease (AD). We assessed
the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) chain for screening preclinical AD,
predicting dementia onset among cognitively healthy (CH) individuals, and the rate of cognitive
decline amongst individuals with mild cognitive impairment (MCI). Methods: Neurofilament light
levels were measured in CSF samples of participants (CH, n = 154 and MCI, n = 32) from the
Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL). Cases of preclinical AD were
identified using biomarker-guided classification (CH, amyloid-β [Aβ]+, phosphorylated-tau [P-tau]+
and total-tau [T-tau]±; A+T+/N±). The prediction of dementia onset (questionable dementia) among
CH participants was assessed as the risk of conversion from Clinical Dementia Rating [CDR = 0] to
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CDR ≥ 0.5 over 6 years. Mixed linear models were used to assess the utility of baseline CSF NfL
levels for predicting the rate of cognitive decline among participants with MCI over 4.5 years. Results:
Neurofilament light levels were significantly higher in preclinical AD participants (CH, A+T+/N±)
as compared to A-T-N- (p < 0.001). Baseline levels of CSF NfL were higher in CH participants who
converted to CDR ≥ 0.5 over 6 years (p = 0.045) and the risk of conversion to CDR ≥ 0.5 was predicted
(hazard ratio [HR] 1.60, CI 1.03–2.48, p = 0.038). CH participants with CSF NfL > cut-off were at a
higher risk of developing dementia (HR 4.77, CI 1.31–17.29, p = 0.018). Participants with MCI and
with higher baseline levels of CSF NfL (>median) had a higher rate of decline in cognition over
4.5 years. Conclusion: An assessment of CSF NfL levels can help to predict dementia onset among
CH vulnerable individuals and cognitive decline among those with MCI.
Keywords: neurofilament light; cerebrospinal fluid; preclinical; early diagnosis; prognosis

1. Introduction
Alzheimer’s Disease (AD) is a disease of multiple etiologies [1]. The associated
neuropathological aberrations initiate at the preclinical stage—a “silent” stage of the AD
continuum devoid of symptoms of cognitive decline, but with evident biochemical changes
in the brain [2]. Preclinical AD is classified into three stages based on amyloid status,
neuronal injury and the presence of subtle cognitive change [3]. Stage one is categorized as
the stage of “asymptomatic cerebral amyloidosis”, with evidence of brain amyloidosis, and
stage two presents evidence of both amyloidosis and neurodegeneration [3]. This staging
aligns with the recently proposed ATN criteria in which individuals with suspected AD can
be classified based on whether they present biomarker evidence of amyloid pathology (A),
tau pathology (T) and neurodegeneration (N) [4]. Pathophysiological biomarkers indicative
of early biochemical aberrations in the brain are needed to identify individuals who are in
the preclinical stage or those likely at risk of developing dementia.
Neurodegeneration initiates early in the AD continuum, believed to be triggered by
several pathological changes, such as amyloidopathy, tauopathy, neuroinflammation and
oxidative stress [5]. Therefore, pathophysiological biomarkers of neurodegeneration should
be explored and evaluated for their ability to screen preclinical AD, predict dementia onset
in cognitively healthy (CH) aged individuals and disease progression (decline in cognition)
in those with MCI. Cerebrospinal fluid (CSF) neurofilament light (NfL) chain is a biomarker
of neurodegeneration whose levels are elevated in AD and associated with central AD
neuropathology [6–10]. Neurofilament proteins, including NfL, act as axonal supports, are
vital for axonal growth and impulse conduction [11] and are shed during axonal degeneration. Elevated levels of CSF NfL associate with cognitive impairment and brain atrophy
over time [6]. Several studies have indicated the potential of plasma NfL for diagnosing
AD [12–15], thus creating a pathway for the development of a non-invasive diagnostic test
for AD. Although NfL non-specifically increases in several neurological diseases, it has the
potential to differentiate AD from other dementias, particularly frontotemporal dementia
(FTD) [16], which has also been validated in meta-analyses conducted by Bridel et al. [17]
and Forgrave et al. [18].
In addition to its diagnostic utility for AD, NfL can be used as a screening biomarker of
early neurodegeneration to predict the risk of dementia onset in the vulnerable population,
as well as a prognostic biomarker of downstream neurodegenerative changes to identify
cognitively impaired individuals who are likely to progress further along the trajectory of
cognitive impairment. Studies indicate that elevated levels of CSF NfL predict the risk of
conversion to mild cognitive impairment (MCI), among CH participants [19], and correlate
with cognitive decline, white matter changes and brain atrophy in participants with MCI [6].
Previously, we confirmed the diagnostic potential of CSF NfL in AD, and the association
of CSF levels with central AD neuropathology and cognition [8]. To further evaluate
and establish the role of CSF NfL as a potential biomarker of preclinical neuropathology,
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sex and apolipoprotein E (APOE) allele data were assessed as part of the cohort demoapolipoprotein E (APOE) allele data were assessed as part of the cohort demographic
graphic characterization. The APOE genotype was assessed using TaqMan genotyping
characterization. The APOE genotype was assessed using TaqMan genotyping assays (Life
assays (Life Technologies, Mulgrave, Australia) for rs7412 (Assay ID: C_904973_10) and
Technologies, Mulgrave, Australia) for rs7412 (Assay ID: C_904973_10) and rs429358 (Assay
rs429358 (Assay ID: C_3084793_20). Figure 1 outlines the study protocol and design.
ID: C_3084793_20). Figure 1 outlines the study protocol and design.

Figure 1. Outline of study protocol and design ATN refers to biomarkers of amyloid pathology
(A), tau pathology (T) and neurodegeneration (N). Abbreviations: Aβ: amyloid-β; CDR: Clinical
Dementia Rating Scale; CDR-SB: Clinical Dementia Rating–Sum of Boxes; CSF: cerebrospinal fluid;
MMSE: Mini Mental State Examination; NfL: neurofilament light; PET: positron emission tomography.
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2.2. Ethics Approval
The AIBL has been approved by the institutional ethics committees of Austin Health,
St. Vincent’s Health, Hollywood Private Hospital and Edith Cowan University. The ethics
approval for this project was additionally provided by Edith Cowan University (#17380).
All participants provided their written informed consent before participating in the study.
2.3. Brain Amyloid-β (Aβ) Imaging and Stratification of Cognitively Healthy Participants
A subset of the CH participants (n = 141) underwent brain PET Aβ imaging with different tracers 11 C-Pittsburgh compound B (11 C-PiB), and 18 F labelled compounds 18 F-florbetapir
and 18 F-flutemetamol. The detailed procedures involving individual ligands/tracers are described elsewhere [22–24]. Each tracer has different pharmacokinetic, binding affinities and
specific reference regions that are reflected in their distinct standardised uptake value ratio
(SUVR) cut-off to distinguish high Aβ (A+) from low Aβ (A−). Therefore, to place the
standardised uptake value ratio (SUVR) of the F-18 amyloid tracers on a single continuous
scale, the SUVRs were linearly transformed into PiB-like SUVR units called the Before the
Centiloid Kernel Transformation (BeCKeT) [25]. Brain Aβ positivity was then determined
based on an SUVR/BeCKeT cut-off value of 1.4 [26].
Using the biomarker-guided ATN classification recommended by the National Institute on Aging and Alzheimer’s Association (NIA-AA) research framework (2018) [4],
CH participants (n = 141) were stratified into the following four groups: (1) normal AD
biomarkers (A-T-N-), (2) preclinical AD pathological change (A+T-N-), (3) preclinical AD
(A+T+/N±) and (4) non-AD pathological change (A-T+/N+). Cut-off values for T-tau and
P-tau positivity (in pg/mL) were determined against AIBL PET-amyloid data using PIB
SUVR of 1.4, using a rank order approach described by Li QX et al., 2015 [27] (T-tau 327.55
[60–70 years)], 497.80 (>70 years); P-Tau 65.56 (60–70 years), 82.85 pg/mL [>70 years]).
2.4. Cognitive Assessments
A neuropsychological battery was used for the cognitive assessments of the participants [20]. CDR scores were used to assess the utility of CSF NfL to predict dementia onset,
i.e., the onset of questionable or very mild dementia (risk of conversion from CDR = 0 to
CDR ≥ 0.5) among CH participants. CDR scores were assessed over 6 years, following
baseline CSF collection (18, 36, 54 and 72 months). A subset of CH participants (n = 124)
who had at least three CDR assessments were included for this analysis. Due to potential
underestimation/overestimation, CH participants who had less than three CDR assessments were not included. Among these 124 participants, 25 converted from CDR = 0 to
CDR ≥ 0.5. MMSE and CDR-SB scores that were assessed at baseline and at follow-up time
points (18, 36 and 54 months), were used for disease prognostic analysis among participants
with MCI (n = 32). MCI participants had an average of three assessments for MMSE and
CDR-SB, and each participant had at least two cognitive assessments.
2.5. CSF Samples
CSF samples were obtained at two centres (Perth and Melbourne), by the usual
procedure of lumbar puncture (LP) according to the protocol outlined by the Alzheimer’s
Biomarkers Standardization Initiative [28]. Samples were centrifuged within 2 h, at 2000× g
for 10 min and then aliquoted into polypropylene tubes (0.5 mL) and stored at −80 ◦ C.
Samples underwent one freeze–thaw cycle to aliquot the samples further.
2.6. Biomarker Analyses
CSF NfL levels were analysed in duplicate using a commercial ELISA (NF-light;
UmanDiagnostics, Umeå, Sweden) following the manufacturer’s protocol. Core CSF
biomarkers (amyloid-β 42, Aβ42; total tau, T-tau and phosphorylated tau, P-tau) were
analysed in duplicate using enzyme-linked immune sorbent assays (ELISAs): INNOTEST
β-AMYLOID (1–42) (Aβ42), INNOTEST hTAU Ag (T-tau), and INNOTEST PHOSPHO-TAU
(181P) (P-tau181P) (Fujirebio, Ghent, Belgium).
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2.7. Statistical Analyses
Statistical analyses were performed using IBM SPSS version 27 (for Microsoft Windows). Cross-sectional differences for continuous variables were assessed with an analysis
of covariance (ANCOVA), controlled for age, sex and APOE genotype (presence of ε4 allele).
Bonferroni corrections were applied for multiple comparisons. Chi-squared tests were used
to compare categorical variables. Where required, assumptions of normality were met by
transforming the variables using a natural logarithm. The ability of CSF NfL to distinguish
CH individuals with preclinical AD (A+T+/N±) from those with normal AD biomarkers
(A-T-N-), and preclinical pathological change (A+T-N-), was assessed via a receiver operating characteristic (ROC) curve analysis. The Cox proportional hazards model was used
to assess the utility of baseline CSF NfL levels for predicting dementia onset, i.e., the risk
of developing questionable or very mild dementia (risk of conversion from CDR = 0 to
CDR ≥ 0.5) among CH participants (n = 124) over 6 years, controlled for age, sex and APOE
genotype (presence of ε4 allele). The effect of baseline CSF levels–high vs. low, on risk of
dementia onset was assessed by dichotomizing CH participants using an optimum cut-off
that provided the maximum value of the Youden index (sensitivity + sensitivity − 1) [29],
following the ROC curve analysis to distinguish converters from non-converters. Kaplan–
Meier survival curves were generated to illustrate the risk of dementia onset, i.e., the
development of questionable dementia over 6 years, in the high CSF NfL group vs. low
CSF NfL group. A log rank test was used to compare survival distributions of the groups.
Mixed linear models were used to assess the utility of baseline levels of CSF NfL,
as well as the utility of core CSF biomarkers (Aβ42, T-tau and P-tau) for predicting the
rate of cognitive decline among participants with MCI over 4.5 years, assessed through
the annual change in MMSE and CDR-SB scores. The rate of cognitive decline in MCI
participants was assessed as a function of CSF biomarkers by using CSF biomarkers (CSF
NfL, Aβ42, T-tau and P-tau) as categorical variables–to assess the effect of high and low
baseline CSF measure on rate of cognitive decline. MCI participants were categorized into
two groups–groups 1 (low CSF biomarker) and group 2 (high CSF biomarker) based on the
50th percentile value (median) of CSF biomarkers amongst the MCI participants. MMSE
and CDR-SB scores were used as dependent variables, and time interval between follow-up
assessments as a continuous variable. For all analyses p > 0.05 was considered significant
and all analyses were controlled for covariates age, sex and APOE genotype, given the
possible effect of these covariates on outcomes assessed.
3. Results
3.1. Utility of CSF NfL to Screen Preclinical AD and Predict Dementia Onset
3.1.1. Screening of Preclinical AD
This analysis was carried out in CH participants (n = 141) who underwent Aβ PET
imaging (A) and had their CSF P-tau (T) and T-tau (N) assessed (Figure 1). Differences
in mean levels of CSF NfL were assessed among the following four groups of CH participants: (1) normal AD biomarkers (A-T-N-, n = 87), (2) preclinical AD pathological change
(A+T-N-, n = 42), (3) preclinical AD (A+T+/N±, n = 7) and (4) non-AD pathological change
(A-T+/N+, n = 5). The results are shown in Table 1. CSF NfL levels were found to be
significantly elevated in the preclinical AD group compared to the normal AD biomarkers
group (p < 0.001; area under the ROC curve [AUC] = 0.79, CI 0.60–0.98, p = 0.011). CSF
NfL levels were also significantly elevated in the preclinical AD group compared to the
preclinical AD pathological change group (p = 0.002, AUC = 0.75, CI 0.53–0.96, p = 0.040).
CSF NfL levels were higher in the preclinical AD group compared to non-AD pathological
change, though not significantly.
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Table 1. Demographic and biomarker characteristics of cognitively healthy participants segregated
using the biomarker guided ATN classification framework.
Cognitively Healthy (n = 141)
Participant Characteristics
Demographics
Number of participants
Sex M/F (% females)
Age at LP in years
APOE ε4 allele not
present/present (% of ε4 carriers)
Neurofilament light
CSF NfL pg/mL

Normal AD Biomarkers
(A-T-N-)

Preclinical AD
Pathological Change
(A+T-N-)

Preclinical AD
(A+T+/N±)

Non-AD
Pathological Change
(A-T+/N+)

87
35/52 (60%)
72 (5.48)

42
24/18 (43%)
74 (4.81)

7
2/5 (71%)
70 (4.63)

5
3/2 (40%)
76 (9.07)

74/13 (15%)

23/19 (45%) $

5/2 (29%)

4/1 (20%)

709 (241.27)

775 (223.58)

1070 (394.11) %,§

885 (355.46)

ATN refers to biomarkers of amyloid pathology (A), tau pathology (T) and neurodegeneration (N). This analysis
was performed on a subset of cognitively healthy participants (n = 141) who underwent Aβ PET (A) imaging and
had measurement of CSF levels of P-tau (T) and T-tau (N). The values of NfL in the table represent raw means (SD)
unless indicated. CSF NfL values were transformed using the natural logarithm and differences were compared
among the groups using ANCOVA after controlling for age, sex and APOE genotype status. Demographic
differences were assessed using Chi-squared tests or ANOVA. $ p = 0.001 vs. Normal AD biomarkers group,
% p < 0.001 vs. Normal AD biomarkers group, § p = 0.002 vs. Preclinical AD pathological change. Abbreviations:
Aβ: amyloid-β; APOE: apolipoprotein E; CSF: cerebrospinal fluid; LP: lumber puncture; NfL: neurofilament light;
PET: positron emission tomography; P-tau: phosphorylated tau; T-tau: total tau.

3.1.2. Prediction of Dementia Onset
Cerebrospinal fluid NfL levels were significantly elevated in participants who converted from CDR = 0 to CDR ≥ 0.5, as compared to non-converters (p = 0.045; Table 2), after
controlling for age, sex and APOE genotype. A Cox proportional hazards model was used
to assess the utility of CSF NfL for predicting dementia onset among CH participants (risk
of conversion from CDR = 0 to CDR ≥ 0.5). CSF NfL levels (Z scores) significantly predicted
the risk of conversion from CDR = 0 to CDR ≥ 0.5 over 6 years, with a hazard ratio (HR) of
1.60 (CI 1.03–2.48, p = 0.038), after controlling for age, sex and APOE genotype. Participants
(CH) whose CSF NfL levels were above the optimum cut-off (>674 pg/mL, determined via
Youden Index; sensitivity 0.88 and specificity 0.50) were at a higher risk of dementia onset
(HR 4.77, CI 1.31–17.29, p = 0.018). The Kaplan–Meier survival curves shown in Figure 2
illustrate that higher CSF NfL levels are predictive of a higher risk of dementia onset (onset
of questionable or very mild dementia) among CH participants. Participants with high
CSF NfL had a lower cumulative survival probability or a higher cumulative hazard of
developing questionable dementia over 6 years, compared to those with low CSF NfL
(p < 0.001). The high CSF NfL group had 22 CH participants who converted to CDR ≥ 0.5
or developed questionable dementia over 6 years, while the low CSF NfL group had three
such participants (p < 0.001; Figure 2).
3.2. Utility of CSF NfL for Predicting Rate of Cognitive Decline in MCI
Cerebrospinal fluid NfL levels (mean levels, pg/mL) were significantly elevated in
participants with MCI vs. CH (p < 0.001) after controlling for covariates age, sex and APOE
genotype (MCI 1017 pg/mL [SD 450.93]; CH 751 pg/mL [253.29]). The prognostic utility of
NfL was assessed using mixed linear models, for predicting the rate of cognitive decline in
participants with MCI over 4.5 years, assessed through the annual change in MMSE and
CDR-SB scores. For comparison, a disease prognostic analysis was also carried out for core
CSF biomarkers (CSF Aβ, T-tau and P-tau). MCI participants (n = 32) were dichotomized
into groups (low and high CSF measure) based on the 50th percentile of CSF measures (NfL
807 pg/mL, Aβ42 650 pg/mL, T-tau 274 pg/mL, P-tau 58 pg/mL). The annual change in
MMSE and CDR-SB scores was assessed in the two groups after controlling for age, sex
and APOE genotype (Table 3).
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Participant Characteristics

Participant
Groups Groups
Participant
p-Value
Converters
Non-Converters
Converters
Non-Converters

p-Value

Demographics
Demographics
Number of participants (n = 124)
25
99
Number of participants (n = 124)
25
99
Sex
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Table 3. Annual rate of change in MMSE and CDR-SB scores in participant groups with MCI–classified
decrease
in MMSE and a higher rate of increase in CDR-SB indicates a higher rate of
based on high and low measure of CSF biomarkers.

CDR-SB
Biomarker

Group 1
(low CSF Biomarker)

p-Value

Group 2
(High CSF Biomarker)

p-Value

CSF NfL
CSF Aβ42 *
CSF T-tau
CSF P-tau

0.19
0.65
0.20
0.18

0.003
<0.001
0.002
0.003

0.68
0.24
0.70
0.78

<0.001
0.004
<0.001
<0.001

Biomarker

Group 1
(low CSF Biomarker)

p-Value

Group 2
(High CSF Biomarker)

p-Value

CSF NfL
CSF Aβ42 *
CSF T-tau
CSF P-tau

−0.12
−1.17
−0.14
−0.04

0.372
<0.001
0.214
0.734

−0.99
−0.02
−1.03
−1.31

0.001
0.875
0.003
<0.001

MMSE

Participants with MCI were dichotomized based on the 50th percentile value for each CSF biomarker. Participants
had four cognitive assessments over 4.5 years, with an average of three assessments (baseline, 18, 36 and
54 months). Results are depicted graphically in Figure 3. * For CSF Aβ42, as expected, the annual change in
cognitive scores was higher in the low CSF Aβ42 group. Abbreviations: AD: Alzheimer’s disease; Aβ: amyloid-b;
CDR-SB: Clinical Dementia Rating Scale–Sum of Boxes; CSF: cerebrospinal fluid; NfL: neurofilament light; MCI:
mild cognitive impairment; MMSE: Mini Mental State Examination; P-tau: phosphorylated tau; T-tau: total tau.

For CSF NfL, the annual change in CDR-SB (rate of increase) and annual change in
MMSE (rate of decrease) was higher in group 2 (high CSF NfL group). A higher rate
of decrease in MMSE and a higher rate of increase in CDR-SB indicates a higher rate of
cognitive decline. The annual change in CDR-SB was 0.68 points in the high CSF NfL
group (p < 0.001), and 0.19 in the low CSF NfL group (p = 0.003). The annual change in
MMSE was −0.99 points in the high CSF NfL group (p = 0.001), and −0.12 in the low CSF
NfL group (p = 0.372). Figure 3A and 3B depict the rate of change in CDR-SB and MMSE
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scores in high and low CSF NfL groups. Similar trends were noted for core CSF biomarkers,
further confirming the potential of CSF NfL to predict rate of cognitive decline in MCI.
For CSF T-tau, the annual change in CDR-SB was 0.70 points in the high CSF T-tau group
(p < 0.001), and 0.20 in the low CSF T-tau group (p = 0.002). The annual change in MMSE
was −1.03 points in the high CSF T-tau group (p = 0.003), and −0.14 in the low CSF T-tau
group (p = 0.214). For CSF P-tau, the annual change in CDR-SB was 0.78 points in the high
CSF P-tau group (p < 0.001), and 0.18 in the low CSF P-tau group (p = 0.003). The annual
change in MMSE was −1.31 points in the high CSF P-tau group (p < 0.001), and −0.04 in
the low CSF P-tau group (p = 0.734). For CSF Aβ42, as expected, the annual change in
cognitive scores was higher in the low CSF Aβ42 group. Lower levels of CSF NfL, T-tau,
P-tau and higher levels of CSF Aβ42 did not indicate the rate of change in MMSE scores.
Therefore, further studies are required to establish the association.
4. Discussion
Cerebrospinal fluid NfL is a biomarker of neurodegeneration whose levels are elevated
in AD and associate with central neuropathological changes–tauopathy, amyloidopathy
and brain atrophy [6–10,16]. Evidence of Aβ (A), and P-tau (T) or T-tau (N) positivity in
CH individuals is indicative of preclinical AD [4]. We noted that CSF NfL levels were
significantly elevated in the preclinical AD group (A+T-/N±) and distinguished preclinical
AD participants from those with normal AD biomarkers (A-T-/N-) with an acceptable
diagnostic accuracy (AUC 0.79). A recent study by Andersson et al., (2020) found that CSF
NfL levels were significantly elevated in CH participants classified as Aβ+ (A+) based
on Aβ42/Aβ40 ratio cut-off [10]. Participants were also classified as neurodegeneration
negative or positive (N− or N+) based on cortical thickness of AD-susceptible temporal
regions [10]. CSF NfL levels were elevated in CH participants classified as A+N+ and
A+N− (p = 0.00125) compared to A-N- for both groups) and much higher in A+N+ (1.66
times higher) [10]. Findings from this study and our study support that CSF NfL can
be used as a potential screening biomarker for preclinical AD. Given that we observed
a fair diagnostic accuracy of CSF NfL for identifying cases preclinical AD, NfL can form
a highly accurate diagnostic classifier in conjunction with biomarkers associated other
pathological changes.
We found significantly elevated baseline levels of CSF NfL in CH individuals who
developed questionable dementia or very mild dementia over 6 years. In addition, the
elevated levels predicted the risk of developing questionable dementia. We noted that
individuals with CSF NfL levels above optimal threshold are at much higher risk of
dementia onset. Future studies with a larger sample size should test our findings by
classifying CH participants using a specific threshold, or into tertiles or quartiles. Since AD
is a neurodegenerative disease, the preclinical stage could be associated with an initial stage
of neurodegeneration whereby clinical symptoms are not evident, but neurodegeneration
exits, though below a certain threshold. Upon disease development or onset, the evolution
of the neurodegenerative process in the brain could be equated to the rate of change in the
severity of clinical symptoms or vice versa [30]. As a biomarker of neurodegeneration, CSF
NfL levels could reflect such neurodegenerative changes, as well as the associated change
in clinical symptoms. Our results indicate that CSF NfL levels predict the rate of cognitive
decline among individuals with MCI. The rate of cognitive decline as measured by the
rate of increase in CDR-SB and rate of decrease in MMSE was higher in MCI participants
with CSF NfL above the threshold (median level). Similar trends noted for core CSF
biomarkers confirm the potential of CSF NfL to predict cognitive decline in individuals
with MCI. Further studies are needed to validate the potential of CSF NfL to predict
cognitive decline in individuals with MCI. Previous studies confirm that higher levels
of CSF NfL predict a higher rate of cognitive decline, as well as the conversion of MCI
to AD [6,31]. Therefore, our results indicate that brains of individuals with MCI, with
high baseline levels of CSF NfL, undergo faster evolution of neurodegenerative processes,
resulting in faster cognitive decline.
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Our results indicate that CSF NfL could be used as a pathophysiological biomarker of
stage-associated neurodegeneration. The identification of stage-associated changes will
help in targeting a focused therapy, which can be applied at an early stage, defined by
specific pathological changes. An early and targeted intervention can help in reducing the
risk of developing dementia or can postpone development. In addition, assessments of
CSF NfL levels can help in enriching the clinical trials, by including individuals who are
likely within the early phase of the AD continuum, based on their biomarker profile [32].
Moreover, outcomes of clinical trials can be ascertained with much more reliability, using
CSF NfL levels as an inclusion criterion, as well as an end point measure, i.e., a treatment
response biomarker to evaluate the effectiveness of therapeutic interventions targeted at
aberrant biochemical pathways promoting axonopathy. Olsson et al. (2019) demonstrated
the utility of CSF NfL as a treatment response biomarker in spinal muscular atrophy [33].
A small cohort of MCI participants represents the major limitation for our study. Given
the small number of participants with MCI, we separated them using the 50th percentile or
median value of CSF NfL, for disease prognostic analysis. A relatively small number of CH
participants could present another limitation. Therefore, the estimated risk of dementia
onset among CH participants (high CSF NfL group vs. low CSF NfL group), and rates of
cognitive decline among participants with MCI could have been overestimated. Findings
should be tested in larger cohorts by stratifying participants into terciles or quartiles, or
dichotomizing them using an optimal cut-off. The utility of CSF NfL to predict the risk of
dementia onset should also be assessed in longitudinal studies using CH participants who
convert to MCI, and to predict disease progression using MCI participants who progress
to AD.
In conclusion, CSF NfL can be used as a pathophysiological biomarker which reflects
early neurodegeneration, and as a prognostic biomarker which reflects downstream neurodegenerative changes along the AD continuum. As a diagnostic biomarker, it can help
to screen preclinical AD and predict the risk of dementia onset. Thereby, it can help to
optimize the drug development process by targeting the right drug candidate, at the right
biochemical pathway and at the right stage. As a prognostic biomarker, it can be used as
a treatment response biomarker for interventions under trial that aim at slowing down
disease progression by combating axonopathy. A biomarker-based diagnostic algorithm,
which includes CSF NfL, could be developed to screen preclinical AD with high accuracy.
To increase the clinical applicability of NfL, future studies should explore the potential of
plasma NfL for screening preclinical AD, predicting the risk of dementia onset among CH
participants, and the rate of cognitive decline in participants with MCI.
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